Board Member’s Major Purchase Signals Confidence in Vivani Medical’s Pipeline

Vivani Med.inc.ew US92854B1098

A significant insider transaction at Vivani Medical, Inc. (Vivani Med.inc.ew) has captured investor attention. Director Gregg Williams has substantially increased his stake in the biotechnology firm with a purchase valued at nearly $2 million, reinforcing his position as a leading shareholder. This move comes as the company approaches pivotal clinical milestones for its proprietary drug-delivery technology.

The transactions, executed on February 15, involved Williams acquiring a total of 1,866,492 common shares in two separate blocks. The majority of these shares, approximately 1.6 million, were obtained at a price of $1.03 per share. An additional 264,551 shares were purchased for $1.26 each. These purchases were made pursuant to pre-existing agreements established in May and August of the previous year.

Following this latest investment, Williams’s total holdings—including both direct ownership and indirect interests held through trusts—have risen to approximately 34.58 million shares.

A Consistent Pattern of Insider Buying

This purchase is not an isolated event but part of a clear pattern of accumulation by the board member. On January 27, Williams participated in a private placement, acquiring over 1.3 million shares at $1.48 per share. Market observers often interpret such sustained investment from a senior director as a strong vote of confidence in the company's long-term prospects, particularly its NanoPortal technology platform.

Vivani Medical is focused on developing subdermal implants designed to provide controlled, long-term delivery of therapeutics. Its primary drug candidates target the treatment of obesity and Type 2 diabetes.

Upcoming Clinical Catalyst in Focus

The market responded favorably to the disclosure of this insider activity. Shares closed at $1.30, maintaining a position within the stock's 52-week range of $0.91 to $1.92.

Investor focus is now shifting to the imminent LIBERATE-1 clinical study. This trial represents the next critical step in validating the NanoPortal platform in human applications and demonstrating the efficacy of the implant technology. The timing of Williams's substantial investment immediately preceding this key data readout is seen as a strategically confident signal.

@ boerse-global.de | US92854B1098 BOARD